Acasă

Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer

Statele Unite

University of Texas M. D. Anderson Cancer Center Jan 26 2025 Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.  The findings, presented today at the American Society of Clinical Oncology Gastrointestinal

din zilele anterioare

Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer https://www.news-medical.net - 26.01.2025 05:52
STIRILE OREI
IN FOCUS: ‘When I die, who’s going to look after you?’ – the pains of caring for adults with disabilities https://www.channelnewsasia.com/ - 06:00
IN FOCUS: ‘When I die, who’s going to look after you?’ – the pains of caring for adults with disabilities https://www.channelnewsasia.com - 06:00
IN FOCUS: ‘I only wish to live one second longer’ – the pains of parents of adults with disabilities https://www.channelnewsasia.com/ - 06:00
IN FOCUS: ‘I only wish to live one second longer’ – the pains of parents of adults with disabilities https://www.channelnewsasia.com - 06:00
Primul câine polițist corgi din China a pierdut un bonus din cauza „conduitei greșite la locul de muncă”. Ce greșeli a făcut patrupedul | VIDEO Libertatea - 21:28
© Copyright 2017 Mediafax SA | Termeni și condiţii | About cookies | Confidentialitate

monitoruldestiri@mediafax.ro

Fotografiile folosite de monitoruldestiri.ro sunt proprietatea Mediafax. Este interzisă republicarea acestora în lipsa unui acord din partea Mediafax. Pentru a obține acest acord, vă rugăm să ne contactați.